India Biotech Group Questions Approval Of Cipla's First Biosimilar
This article was originally published in PharmAsia News
India's Association of Biotechnolegy Led Enterprises questions government approval of Cipla's recently launched Etacept (etanercept) for rheumatism as its first biosimilar drug, suggesting it may not have followed guidelines.
You may also be interested in...
Executives On The Move: BMS Taps Barclays Exec For Strategy Spot, Epizyme Selects Science Chief And A Board Election At ADC Therapeutics
Bristol-Myers Squibb taps Barclays chair of global life sciences as it EVP, strategy and business development, and cancer therapeutics firm Epizyme Inc. selects a chief scientific officer. At ADC Therapeutics, an oncology drug development company, a new chairman is elected.
Non-CE-marked products on the EU market, virtual notified body audits, free standards and the Commission bid to pause the MDR. March has seen unprecedented developments as COVID-19 has railroaded through the sector decimating regulatory rules and plans.